The UK government will indefinitely ban prescriptions of puberty blockers for under-18s in cases of gender dysphoria, making it the latest country in Europe to enact restrictions on gender-affirming care for adolescents.
Health Secretary Wes Streeting told the House of Commons on Wednesday that he made the decision after considering recommendations by the Commission on Human Medicines, which advises ministers on the safety of medical products. A review by Dr. Hilary Cass published in April found that the long-term benefits for treating gender-related distress were unproven.
“After thoroughly examining all the available evidence, they have concluded that prescribing puberty blockers ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.